Lord, Abbett & Co. LLC Crinetics Pharmaceuticals, Inc. Transaction History

Lord, Abbett & Co. LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$50.66 - $60.69 $1.09 Million - $1.3 Million	-21,493 Reduced 2.88%	724,625 $37.1 Million
Q3 2024 Nov 14, 2024	SELL	$43.83 - $54.98 $6.22 Million - $7.8 Million	-141,803 Reduced 15.97%	746,118 $38.1 Million
Q2 2024 Oct 07, 2024	SELL	$42.12 - $51.91 $3.23 Million - $3.98 Million	-76,647 Reduced 7.95%	887,921 $39.8 Million
Q2 2024 Aug 14, 2024	SELL	$42.12 - $51.91 $3.23 Million - $3.98 Million	-76,647 Reduced 7.95%	887,921 $39.8 Million
Q1 2024 Oct 07, 2024	BUY	$34.76 - $46.81 $6.51 Million - $8.77 Million	187,280 Added 24.09%	964,568 $45.2 Million
Q1 2024 May 09, 2024	BUY	$34.76 - $46.81 $6.51 Million - $8.77 Million	187,280 Added 24.09%	964,568 $45.2 Million
Q4 2023 Oct 07, 2024	SELL	$25.62 - $37.07 $2.83 Million - $4.1 Million	-110,633 Reduced 12.46%	777,288 $27.7 Million
Q4 2023 Feb 12, 2024	BUY	$25.62 - $37.07 $19.9 Million - $28.8 Million	777,288 New	777,288 $27.7 Million

235

87M

40K

162K

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $1.68B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Lord, Abbett & Co. LLC with notifications on news.